Navigation Links
BioParadox Announces Partnership with Fogarty Institute for Innovation
Date:2/2/2012

MENLO PARK, Calif., Feb. 2, 2012 /PRNewswire/ -- BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced a strategic alliance with Fogarty Institute for Innovation. 

"We are delighted to begin working with the Fogarty Institute for Innovation known for its commitment to developing creative solutions for patients with challenging problems.  The Fogarty Institute's unique programs to support medical innovators by providing important business, technical, and clinical input offers BioParadox the opportunity to rapidly advance its novel Platelet-Cell Therapy (PCT) for the treatment of cardiovascular disease," said Allan Mishra, MD, Founder of BioParadox. 

Speaking at the January 2012 Conference on Cell Therapy for Cardiovascular Disease in New York, Todd Brinton, MD, presented data supporting PCT for peripheral vascular disease.  BioParadox was also recently awarded a United States patent covering this technology. 

About BioParadox

BioParadox is innovating the use of Platelet-Cell Therapy (PCT) for the treatment of cardiovascular disease. The company's first products, VitaKine® and RevaTen®, are proprietary formulations that have been shown to enhance cardiovascular function. They are produced exclusively by BioParadox.

For more information, please visit: BioParadox.com or e-mail: info@bioparadox.com

About the Fogarty Institute for Innovation

The Fogarty Institute for Innovation is an educational 501(c) (3) non-profit committed to the mission of improving patient care by supporting revolutionary medical innovation. The Institute offers promising innovators world-class technical and business mentoring, laboratory space, and clinical support to propel medical innovations from conception to application. Furth
'/>"/>

SOURCE BioParadox, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Regenerative Medicine Company BioParadox adds Healthcare and Medical Device Expert, Michael Kleine, to its Board of Directors
2. Hybrid Fuels, Inc. Announces FDA Approved Lab Selection for Azul Instant™ - "Be Ready in an Instant"
3. Nautilus Neurosciences Announces New Patent Issued
4. Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe
5. Sapio Sciences Announces Exemplar Dx LIMS for Laboratories in the Burgeoning MDx Market
6. Medical Alarm to Begin Fulfillment of MediPendant™ Against Largest Purchase Order - Announces Additional Warrant Cancellations
7. RemedyMD Announces Investigate Cell Therapy, a Revolutionary Research Management System for Blood and Marrow Transplant Centers
8. China Health Resource Announces Professor Liang Li, World Renowned TCM Expert, to Lead Gastrodia Deep Processing Research
9. Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
10. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
11. Oclaro Announces Second Quarter Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern ... suffering from depression . , A team ... mechanism by which ghrelin (a hormone with natural anti-depressant ... a potentially powerful new treatment for depression in the ... , The study, published online in April,s issue ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... pill that will help protect and even treat hearing loss from ... say it has picked up steam in just the past few ... Marines will face rifle training with not only foam plugs in ... herbal tea. ,They'll take it with every meal during their ...
... observational studies previously conducted in elderly populations have ... performed before intracoronary stents and use of glycoprotein ... Hanoch Hod, of Chaim Sheba Medical //Center in ... patients aged 70 or older treated for ST-elevation ...
... new studies have identified genetic activity that appears to ... alters a person's perceptions of reality, emotions and thought ... of the world's population, typically surface during the late ... Rockefeller, University in New York and colleagues identified two ...
... vasectomy, contraception is typically left up to the woman. ... in a woman's contraceptive repertoire. Until now, men have ... searching for new options. Now, they may have one.// ... 12 percent. Vasectomies are considered permanent. Dr. Wang, of ...
... periods ,Seasonale, a new drug approved by the Food ... women's periods to four a year by taking the hormones ... spans of time.// ,Seasonale would be another alternative ... prevention of pregnancy and are comfortable taking a hormonal contraceptive, ...
... for some doctors who think it's time to replace the ... invented it in the early 1800s. "The stethoscope is based ... to distinguish between a heart that is beating well, and ... heart muscle is very weakened, but unless that weakening leads ...
Cached Medicine News:Health News:Pill might be able to reduce the damage loud noise does to your hearing 2Health News:Pill might be able to reduce the damage loud noise does to your hearing 3Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Gene Activity connected to Schizophrenia 2Health News:New birth control to limit women's periods 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: